CLINICAL STUDY PROTOCOL
Study Title: A Phase 1 Open -Label Study  to Evaluate the Pharmacokinetics of 
GS-9876 in Subjects with Impaired Renal Function
Sponsor: [COMPANY_009] Sciences, Inc.
[ADDRESS_340987]
Foster City , CA [ZIP_CODE]
IND No.:
EudraCT No.:[PHONE_5795]-003823-47
Indication: Inflammatory  Diseases
Protocol ID: GS-US-
379-1932
[COMPANY_009] 
Medical Monitor Name:
[CONTACT_10880]:
Fax:
Mobile :
Email:
Protocol Version/Date: Original : 10October 2016
Amendment 1: 09January [ADDRESS_340988] OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 12
1. INTRODUCTION .............................................................................................................................................. 16
1.1. Background ............................................................................................................................................ 16
1.2. GS-9876 ................................................................................................................................................. 16
1.2.1. General Information ............................................................................................................. 16
1.2.2. Preclinical Pharmacology, Pharmacokinetics and Toxicology ............................................. 17
1.2.3. Additional Clinical Studies of GS -9876 ............................................................................... 19
1.3. Rationale for This Study ........................................................................................................................ 20
1.4. Rationale for the Dose Selection ............................................................................................................ 21
1.5. Risk/Benefit Assessment for the Study .................................................................................................. [ADDRESS_340989] Selection ............................................................................................ 28
4.2. Inclusion Criteria .................................................................................................................................... 28
4.2.1. All Subjects .......................................................................................................................... 28
4.2.2. For Subjects w ith Renal Impairment .................................................................................... 29
4.2.3. For Healthy Matched Controlled Subjects (Subjects w ith Norm al Renal 
Function) .............................................................................................................................. 30
4.3. Exclusion Criteria ................................................................................................................................... 30
4.3.1. All Subjects .......................................................................................................................... 30
4.3.2. For Subjects w ith Renal Impairment .................................................................................... 32
4.3.3. For Healthy Matched Controlled Subjects (Subjects w ith Norm al Renal 
Function) ...............................................................
............................................................... [ADDRESS_340990] Enrollment and Treatment Assignment ..................................................................................... 38
6.2. Pretreatment Assessments ...................................................................................................................... 41
6.2.1. Screening Visit ..................................................................................................................... 41
6.2.2. Admissio n Assessments ....................................................................................................... 41
6.3. Check -in Assessments ............................................................................................................................ 42
6.4. Treatment Assessments .......................................................................................................................... 42
6.5. Posttreatment Assessments .................................................................................................................... 42
6.6. Assessments for Premature Discontinuation from Study ....................................................................... 42
6.7. Criteria for Discontinuation of Study ..................................................................................................... 42
6.8. Pharm acokinetic Assessments ................................................................
................................................ 43
6.8.1. Plasma PK Co llection ........................................................................................................... 43
6.8.2. Urine Pharmacokinetic Collection ....................................................................................... 43
6.9. Safety Assessments ................................................................................................................................ 43
6.9.1. Electrocardiogram Assessment ............................................................................................ 43
6.9.2. Physical Examination ........................................................................................................... 44
6.9.3. Vital Signs ............................................................................................................................ 44
6.9.4. Body  Mass Index .................................................................................................................. 44
6.9.5. Clinical Laboratory Tests/Assessments ................................................................................ 44
6.9.6. Creatinine Clearance and Estimated Glomerular Filtration Rate ......................................... 45
6.9.7. Adverse Events/Concomitant Medications/Protocol Restrictions ........................................ 45
6.10. Sample Storage ....................................................................................................................................... 45
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ................................
............................................... 46
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 46
7.1.1. Adverse Events ..................................................................................................................... 46
7.1.2. Serious Adverse Events ........................................................................................................ 46
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessment
s as 
Adverse Events or Serious Adverse Events ......................................................................... 47
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 47
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 47
7.2.2. Assessment of Severity ........................................................................................................ 48
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to [COMPANY_009] ....................................................................................................................... 48
7.3.1. Requirements for Collection Prior to Study Drug Initiation: ............................................... [ADDRESS_340991]/Independent Ethics Committee Revie w and 
Approval ............................................................................................................................... 56
9.1.3 . Informed Consent ................................................................................................................. 56
9.1.4. Confidentiality ...................................................................................................................... 57
9.1.5. Study Files and Retention of Records .................................................................................. 57
9.1.6. Case Report Forms ............................................................................................................... 58
9.1.7. Study Drug Accountability and Return ...............................................................
................. 59
9.1.8. Inspections ............................................................................................................................ 59
9.1.9. Protocol Compliance ............................................................................................................ 59
9.2. Sponsor Responsibilities ........................................................................................................................ 60
9.2.1. Protocol Modifications ......................................................................................................... 60
9.2.2. Study Report and Publications ............................................................................................. 60
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 60
9.3.1. Payment Reporting ............................................................................................................... 60
9.3.2. Access to Information for Monitoring .................................................................................. 60
9.3.3. Access to Information for Auditing or Inspections .............................................................. 60
9.3.4. Study Discontinuation .......................................................................................................... 61
10. REFERENCES ................................................................................................................................................... 62
11. APPENDICES .................................................................................................................................................... 63
Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................... 64
Appendix 2. Management of Clinical and Laboratory Adverse Events ...................................................... 65
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 66
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v 4.[ADDRESS_340992] OF IN -TEXT TABLES
Table 1-1. Margins for GS -9876 Based on Systemic Exposure Relative to the Observed 
Human Exposure at 20 mg (AUC) ......................................................................................... [ADDRESS_340993]
Foster City, CA [ZIP_CODE]
Study Title : APhase 1 Open- Label Study  to Evaluate the Pharmacokinetics of 
GS-9876 in Subjects with Impaired Renal Function
IND Number:
EudraCT Number:[PHONE_5795]-003823-47
Study Centers 
Planned:Multiple center sin the [LOCATION_002] , German y, and New Zealand
Objectives: The primary  objective of this study  is as follows:
To evaluate the pharmacokinetics (PK) of GS- 9876 in subjects 
with impaired renal function relative to matched, healthy  controls
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerability  of GS -9876 in subjects with 
normal and impaired renal function
Study Design: Phase 1, open -label, parallel -group, adaptive, single -dose, multi -
center, pharmacokinetic study  
Number of Subjects 
Planned:This study  will target e nrolling 20 subjects per cohort, and a 
maximum of 60 subjects using an adaptive design that includes up to 
3 enrolled cohorts of subjects with renal impairment and matched 
healthy  controls. Based on safet y and PK results from subjects with 
moderate renal i mpairment (Cohort 1), subjects with severe renal 
impairment (Cohort 2) and/or mild renal impairment (Cohort 3) will 
be enrolled as follows:
Cohort 1 (Moderate Renal I mpairment): Up to 20 subjects (10 per 
group, moderate renal impairment and matched healthy controls) 
for 8 evaluable subjects per group.
Adaptive Cohort 2 (Severe Renal Impairment): Up to 20 subjects 
([ADDRESS_340994]) for 8 evaluable subjects per group.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 7 09 January 2017Adaptive Cohort 3 (Mild Renal I mpairment): Up to 20 subjects 
([ADDRESS_340995]) for 8 evaluable subjects per group.
Adaptive Cohorts 2 and/or 3 will be enrolled as determined b y safet y 
and/or PK data in Cohort 1. Specificall y, Cohort 2 (Seve re Renal 
Impairment) will be evaluated if supported b y safety  and/or PK data 
from Cohort 1 (Moderate Renal I mpairment). Cohort 3 (Mild Renal 
Impairment) will be evaluated if supported b y safety  and if substantial 
changes ( ≥ 2-fold mean difference from matc hed controls) in the 
exposure of GS -[ADDRESS_340996] within a cohort.
Target Population: Male and non- pregnant/non -lactating female subjects, ages ≥ 18 and 
≤ 75years, with normal or impaired renal function. Subjects with 
renal impairment must have a renal impairment classification (mild, 
moderate, or severe) at Screening that has been unchanged during the 
[ADDRESS_340997] in the control 
group will be matched for age (± 10 years), gender, and bod y mass 
index (± 20%, 18 kg/m2and 36 kg/m2).
Duration of Dosing: 1 day
Study  Duration: 15 day s
Diagnosis and Main 
Eligibility  Criteria:Subjects will comprise those with normal and impaired renal 
function. Those with impaired renal function will be categorized 
based on estimated creatinine clearance (CLcr) usi ng the 
Cockcroft -Gault (C -G) equation for renal function as recommended 
by [CONTACT_2165] (FDA) and international 
guidance documents. Classification of renal impairment is defined as 
follows:
Mild: CLcr 60 -89 mL /min
Moderate: CLcr 30-59 mL /min
Severe: CLcr 15 -29 mL /min
Severe renal impairment subjects requiring or anticipated to require 
dialy sis within [ADDRESS_340998] of matched control subjects with normal renal 
function (CLc r ≥ 90 mL/min).
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 8 09 January 2017Subjects will also be categorized using the estimated glomerular 
filtration rate (eGFR) using the Modification of Diet in Renal Disease 
(MDRD) Study  equation and select results from this study  will also 
be anal yzed using these criteria {National Institute of Diabetes and 
Digestive and Kidney  Diseases (NIH) 2016
}.
eGFR (mL/min/1.73 m2) =175× (S cr)-1.154× (Age)-0.203× (0.742 if 
female) × (1.212 if African American)
Normal: eGFR ≥ 90 mL /min/1.73 m2
Mild: eGFR 60 -89 mL/min/1.73 m2
Moderate: eGFR 30 -59 mL/min/1.73 m2
Severe: eGFR 15 -29 mL/min/1.73 m2
Study  Procedures/
Frequency :Following completion of Screening and Day  -1 assessments, eligible 
subjects will receive a single oral dose of the following stud y drug on 
Day 1:
20 mg GS-
9876 (2 × 10 mg tablet) in the fasted state
Dosing in a matched subject with normal renal function will occur 
after the corresponding subject with impaired renal function has 
completed his/her PK assessment, except for control subjects that 
were alread ymatched to a subject with impaired renal function in a 
previous cohort, as permitted in adaptive Cohorts 2 and 3.
Study Visits and Confinement
Following screening and Day  -1 procedures, eligible subjects will be 
confined to the stud y center beginning Day 
-1 until the completion of 
assessments on Day  6. Subjects will return 14 (± 1) day s after last 
dose for an in -clinic follow up visit (ie. Day  15).
Study Drug Administration
Following an overnight fast of at least 8 hours (no food or drink 
except water), st udy drug will be administered in the morning with 
[ADDRESS_340999] until after collection 
of the 4- hour PK sample, relative to study  drug dosing. Additionally , 
subjects will be restricted from water consumption 1 hour before until 
2hours after dosing, except for the 240 mL given with the study  
treatment.
Pharmacokinetic Assessments
Plasma PK collection
Plasma concentrations of GS -9876 will be measured and PK 
parameters determined. Plasma concentrations of GS-9876 
metabolites may be determined and pharmacokinetics explored, as 
applicable.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 9 09 January 2017Intensive PK sampling will occur relative to dosing of GS -9876 at the 
following time points:
Day 1: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 60, 
72, 96 and 120 hours postdose
Protein binding of GS -9876 (and its metabolites, as applicable) will 
be assessed at or near their T maxtimepoint(s) as well as another later 
time point.
Urine PK Sampling
Urine PK samples will be collected relative to dosing of GS -9876 at 
the following intervals:
Day 1: Pre -dose void, 0-6, 6-12, 12-24, 24-48, 48-72, 72- 96 and 
96-120 hours postdose 
Urine concentrations of GS -9876 and/or metabolites may  be 
determined and PK parameters estimated.
Safety Assessments
Complete physical exam: Screening, Day s -1, 6, and at the follow -
up
visit 14 (± 1) day s after last dose or at the Earl y Termination (ET)
visit, if applicable
Symptom driven physical exam: every  day during confinement as
needed, based on reported signs and s ymptoms
Vital signs (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature):
Screening, Day s -1, 1 (predose, 1, 3, 6, and 12 hours postdose), 2, 3, 
4, 5, 6, and at the follow -up visit 14 (± 1) day s after last dose or at the 
ETvisit, if applicable
Height: Screening
Weight: Screening, Day  -1
Clinical laboratory tests (blood chemistry, and urinalysis):   
Screening, Day s -
1, 1 (4 hours postdose), 2, 3, 6, and at the follow - up 
visit 14 (± 1) day s after last dose or at the ET visit, if applicable
Clinical laboratory tests (hematol ogyand coagulation
):Screening, 
Days -1, 1 (4 hours postdose), 3, 6, and at the follow -up visit 14 (± 1) 
days after last dose or at the ETvisit, if applicable.
Urine Drug and Alcohol Assessments: Screening, Day  -1
12-lead ECG: Screening, Day s -1, 1 (post dose) , 6, and at the 
follow -up visit 14(± 1) day s after last dose or at the ETvisit, if 
applicable
Serum Pregnancy Test (women of childbearing potential only):
Screening, Day  
-1, 6, and at the follow -up visit 14 (± 1) day s after last 
dose or at the 
ETvisit, if applicable
GS-[ADDRESS_341000] (HBV, HCV, HIV): Screening
Assessment of adverse events and concomitant medications will 
continue throughout the study . 
Test Product, Dose, 
and Mode of 
Administration:GS-9876 2 × 10 mg tablet, oral, administered fasted
Criteria for 
Evaluation:
Safety : Safety  will be assessed during the study  through the reporting of AEs, 
and by  [CONTACT_90258], phy sical examinations, vital signs, 
and ECGs at various time points during the stud y. Concomitant 
medication usage will be assessed throughout the study .
Efficacy : Not applicable .
Pharmacokinetics: The following plasma PK parameters willbe calculated, as 
appropriate: C max, Tmax, Clast, Tlast, λz, AUC last,AUC 0-24,AUC inf, 
%AUC exp, t½,CL/F, and V z/F.
PK of predominant GS -9876 metabolites (if applicable) may  be 
explored. In addition, urine parameters (e.g. renal clearance and 
percentage of dose excreted in urine) may be estimated.
Statistical Methods: Pharmacokinetics :
Pharmacokinetic parameters for GS -9876 will be listed and 
summarized by  [CONTACT_210141] (normal, mild, moderate, and 
severe impairment) using descriptive statistics.
An anal ysis of variance appropriate for a parallel design will be fit to 
the natural logarithm -transformed PK parameters ( AUC last, AUC inf,
and Cmax) for GS -9876. Two- sided 90% confidence intervals (CIs) 
will be constructed for the geometric least -squares means (GLSM) 
ratio of PK parameters for GS -9876 in groups of subjects with renal 
impairment versus matched controls.
Safety :
Safety  data will be listed by  [CONTACT_279374]/abnormality  or descriptive 
statistical summaries, as appropriate. Sample Size:  
With 16 (8 per group) evaluable subjects, the estimated two- sided 
90% CI  of the GLSM ratio of test versus reference groups, with 
regards to PK parameters (AUC and Cmax) would be within (50%, 
200%) with over 95% probability . This calculation is based on a t wo 
GS-[ADDRESS_341001] deviation (SD) of no more than 0.[ADDRESS_341002] dose levels (15 mg and 
30 mg) of the dose in this study . An overage of [ADDRESS_341003] op-outs, thus requiring a 
total enrollment of 20 subjects (10 per group) for each cohort.
This study  will be conducted in accordance with the guidelines of Good Clinical Practices 
(GCPs) including archiving of essential documents.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 12 09 January 2017GLOSSARY OF ABBREVIATI ONS AND DEFINITION O F TERMS
λz terminal elimination rate constant, estimated by [CONTACT_279375]
%AUC exp percentage of AUC extrapolated betw een AUC lastand AUC inf
C degrees Celsius
ADME absorption, distribution, metabolism, and elimination
AE adverse event
AhR aryl hydrocarbon receptor
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the concentration versus time curve
AUC inf area under the concentration versus time curve extrapolated to infinite time, 
calculated as AUC last+ (C last/λz)
AUC last area under the concentration versus time curve from time zero to the last 
quantifiable concentration
AUC tau area under the concentration versus time curve over the 
AUC 0-[ADDRESS_341004] cancer resistance protein
BLQ below  limit of quantitation
BMI body mass index
bpm beats per minute
BUN blood urea nitrogen
CBC complete blood count
CD Cluster of differentiation
CFR Code of Federal Regulations
C-G Cockcroft -Gault
CI confidence interval
CIA collagen -induced arthritis
CL/F apparent oral clearance after administration of the drug:
CL/F = Dose/AUC inf, where “Dose” is the dose of the drug
Clast last observed quantifiable concentration of the drug
CL cr creatinine clearance
Cmax maximum observed concentration of drug
CNS central nervous system
CPK creatine phosphokinase
CRF case report form
CRO contract (or clinical) research organization 
GS-[ADDRESS_341005] -square smean
GN glomerulonephritis
HBV hepatitis B virus
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HDL high-density lipoprotein
HDPE high-density polyethylene
HIV, HIV-1 human immunodeficiency virus, type 1
HLGT high-level group term
HLT high-level term
IB investigator’s brochure
IC50 half maximal inhibitory concentration
ICF informed consent form
ICH International Conference on Harmonization (of Technical Requirements for 
Registration of Pharmaceuticals for Human Use)
ID identification
GS-[ADDRESS_341006]
IND investigational new drug (application)
INR international normalized ratio
IRB institutional review board
IUD intrauterine device
LAM lactational amenorrhea method
LDH lactic acid dehydrogenase
LDL low-density lipoprotein
LLT lower-level term
LLOQ lower limit of quantitation
MCV mean corpuscular volume
MDRD Modification of Diet in Renal Disease
MedDRA Medical Dictionary for Regulatory Activities
MM medical monitor
mTOR mammalian target of rapamycin
nM nanometers
NOAEL no-observed -adverse -effect level
NOEL no-observed -effect level
NSAID nonsteroidal anti -inflammatory drug
OATP organic anion -transporting polypeptide
PD pharmacodynamic(s)
PG pharmacogenomics
P-gp P-glycoprotein
PI [INVESTIGATOR_19959](s)
PRinterval electrocardiographic interval occurring betw een the onset of the P w ave and the 
QRS complex representing time for atrial and ventricular depolarization, 
respectively
PT preferred term
PTT partial thromboplastin time
PXR pregnane X receptor
Q1 first quartile
Q3 third quartile
QA quality assurance
QD quaque die (every day or once daily)
QRS electrocardiographic deflection betw een the beginning of the Q w ave and 
termination of the S wave, representing time for ventricular depolarization
GS-[ADDRESS_341007] time (observed time point) of C last
Tmax the time (observed time point) of C max
TNF tumor necrosis factor
TOST two one -sided t ests
TQT thorough QT
TV television
t1/2 estimate of the terminal elimination half -life of the drug, calculated by [CONTACT_279376] 2 by [CONTACT_90262] (λ z)
ULN upper limit of normal
μM micrormeter
US, [LOCATION_003] [LOCATION_002], [LOCATION_002] of America
Vz/F apparent volume of distribution of the drug
WBC white blood cell
WHO World Health Organization
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 16 09 January [ZIP_CODE]. INTRODUCTION
1.1. Background
GS-9876 is a potent and selective inhibitor of SYK and is being developed by [CONTACT_10869], 
Inc. ([COMPANY_009]) as an oral agent for the treatment of inflammatory  diseases. Spleen ty rosine kinase 
is a nonreceptor cy toplasmic ty rosine ki nase primarily  expressed in cells of hematopoietic 
lineage, where it functions as a key  signaling molecule mediating immunoreceptor signaling in a 
range of cells involved in inflammatory  disease . Given its central role in immune cell signaling, 
inhibition of SYK is expected to affect multiple steps in the pathogenesis of several autoimmune 
diseases such as rheumatoid arthritis ( RA)resulting in pleiotropic anti -inflammatory  effects.
R
heumatoid Arthritis is a chronic, s ystemic inflammatory  disease that affec ts approximately  
1.3 million adults in the [LOCATION_002] ( US) {Helmick et al 2008 }. Rheumatoid Arthritis manifests 
principally  as an attack on peripheral joints and may  lead to marked destruction and deformit y of 
joints, with considerable disability  and impact on quality  of life. It is characterized by  [CONTACT_279377], sy novial inflammation with formation of 
pannus tissue, and 
erosion of underl ying cartilage and bone. Although people of any  age can be affected, the onset 
of RAis most frequent between the age of [ADDRESS_341008] been 
implicated in its pathogenesis. Subjects with RA experience a high ri sk of disability  and 
mortality  {Arthritis Foundation 2008 }.
Despi[INVESTIGATOR_279364] y available treatment options for RA, there is still a need for new treatments 
because not all subjects respond adequately  (or maintain resp onse) to current therapi[INVESTIGATOR_279365]/or intolerance that limit the use of such therapi[INVESTIGATOR_014]. All currentl y 
available treatments have safet y considerations that can develop during chronic use that may  
require a change to a dif ferent therapy . The unmet medical need for new therapeutic options with 
a favorable efficacy  and safet y profile that do not require injection/infusion have prompted 
efforts to develop oral small molecule inhibitors of protein kinases involved in cellular s ignaling 
associated with theunderly ing RA disease pathology . 
There are several potential causes of nephropathy  in patients with RA: drug
-related renal disease, 
where drugs such as NSAIDs and DMARDs, secondary  renal am yloidosis and various t ypes of 
glomer ulonephritis (GN) {Karie et al 2008 }.Kidney  disease and impairment is thought to be 
highl y prevalent in the RA population and therefore a renal impairment study is indicated. 
1.2. GS-
9876
1.2.1. General Information
For further information on GS-9876 refer to the current investigator’s brochure (IB).
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 17 09 January [ZIP_CODE].2.2. Preclinical Pharmacology , Pharmacokinetics and Toxicology
[IP_ADDRESS]. Nonclinical P
harmacology and Safet y Pharmacology
GS-9876 is a selective and potent adenosine triphosphate ( ATP )-competitive inhibitor of SYK
with an IC50 value of 9.[ADDRESS_341009] 7 -fold more selective biochemically  
for SYK relative to all other protein kinases assayed. Functionall y, GS-9876 inhibited 
anti-IgM-induced BCR/ SYK -mediated phosphory lation and activation of multiple downstream
signaling pathway s in primary  human B -cells, suppressed anti
-IgM mediated CD69 and CD86 
activation marker expression on B -cells, and proliferation of peripheral B cells.  GS -9876 
showed a 12- fold selectivity  for B -cell proliferation versus anti-CD3/anti -CD28 costimulation of 
T-cell proliferation .  Furthermore, GS -9876 inhibited immune -complex stimulated TNF and 
IL-1release from primary human monocy tes. In human blood, GS-9876 inhibit edSYK
autophosphory lation, anti-IgD/BCR -induced CD69 expression on B -cells, and
anti-FceRI -stimulated CD63 expression on basophils with geometric mean EC 50values ranging 
from 171 nM to 301 nM .
In two independent rat collagen -induced arthritis (CI A) models in animals with establishe d 
disease, treatment with GS -9876 caused significant and dose -
dependent amelioration of clinical 
and histopathology  parameters when dosed either earl y (at initiation of ankle swelling) or late 
(attime of peak ankle swelling) after disease onset. Histologi cal evaluation of joints in the 
animals from the study  demonstrated that GS- 9876 treatment reduced pannus formation, 
cartilage damage, bone resorption, and periosteal bone formation with an effective dose inducing 
a 50% inhibitory  effect (ED 50) of < 6.25 m g/kg, QD and 11.6 mg/kg, QD in the earl y and late 
CIA models, respectively.  Significant efficacy  was seen with GS -9876 doses that produced 
Caveexposures that were calculated to inhibit SYK phosphory lation by  50% (EC 50).  GS -9876 
was well tolerated at all doses andthere were no treatment- related adverse effects on body  
weight, food and drink intake, in- life observations or clinical pathology  parameters.   
Safety  pharmacology  studies were conducted to exam ine the potential effects of GS- 9876 on the
cardiovascular s ystem, respi[INVESTIGATOR_2133] , and central nervous s ystem ( CNS ). There were no 
clinically -relevant effects on the respi[INVESTIGATOR_696] ,and CNS sy stems af ter single oral doses up to 
300mg/kg. C ardiovascular effects in telemetered cy nomolgus monkey s at≥ 20 mg/kg included 
prolonged QTc interval from 5 through 25 hours postdose, slightly  higher sy stolic, diastolic, and 
mean arterial pressure with lower heart rate through 6 hours postdose, and higher heart rate from 
9 through 25 hours postdose. While diff erences in QTc interval were generally  small, the 
changes were of sufficient magnitude to be considered biologicall y relevant .There were no 
inhibitory  effects on the hERG potassium current when GS -9876 was tested up to a free drug 
concentration of 30 μM, approximately  207- fold above the observed stead y state C maxat a 30 mg 
QD clinical dose. Further, no cardiovascular effects were observed in telemetered cy nomolgus 
monkey s administered GS -9876 for 13 weeks at doses up to 15 mg/kg/day . The potential for 
GS-
9876 to prolong the QTc interval was assessed with intensive time matched ECG monitoring 
in [COMPANY_009] studies GS -US-379- 1372 and GS -US-379- 1900 (cohorts 1 and 2), and no clinical 
significant change in time matched QTc intervals was observed. No clinical significant changes 
in vital signs during serial vital sign measurements were observed.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 18 09 January [ZIP_CODE].2.2.2. Nonclinical Toxicology
In the repeat -dose studies, the toxicity  profile of GS -9876 was assessed in rats and monkey s 
administered GS -9876 orally  for up to 26 weeks. Dose -dependent effects on ly mphocy tes in both 
rats and monkey s were consistent with the expected pharmacology of SYK inhibition. Effects on 
hemostasis were observed in rats and monkey s, with increased ery throcy te turnover in rats at 
≥ 10 mg/kg/day , and he morrhage and thrombosis in monkey s at ≥ 20 mg/kg/day . At higher doses 
in rats ( ≥ 30 mg/kg/day ), mortality  associated with bacterial infections, likely resulting from the 
immunomodulatory  activity  of GS -9876, was seen. Additional findings included ly mphoid 
depletion in the thy mus, changes in the pancreas, with secondary  effects related to the 
immunomodulatory  activity  of GS -9876, and likely  opportunistic bacterial infection, observed in 
several tissues. The no -observed-adverse- effect level (NOAEL) in rats wa s 10 mg/kg/day  after 
26 weeks dosing. For the 20 mg single dose proposed in this study , estimated exposure margins 
are 3.1-/7.6- fold based on exposures at the NOAELs in the 26 week stud y in male/female rats.  
Subjects will be closely  monitored for any  infection andchanges in the differential CBC.
In monkey s, the NOAEL in the 28
-day study  was identified at 10 mg/kg/day , which was 
associated with AUC 0-24hrof 4290 ng •hr/mL. In the 13- week monkey  study, there were no effects 
on hemostasis, and the NOAEL was the high dose 
of 15 mg/kg/day . In the 39- week monkey  
study , there was no evidence of effects on hemostasis at the high dose of 15 mg/kg/day , and the
NOAEL was 15 mg/kg/day , associated with an AUC0
-24hr of 8040 ng•h/mL .For the 20 mg 
single dose proposed in this study , the estimated exposure margin is2.8-fold based on exposures 
at the 15 mg/kg/day  NOAEL  in the 39-week monkey  study .
In GL P range -finding developmental toxicity  stud ies 
in pregnant rats and rabbits, n o 
Caesarean- sectioning, litter parameters, or gross external or visceral alterations were affected b y 
GS-9876 at dose levels up to 100 mg/kg/day in rats, or up to 30 mg/kg/day  in rabbits. In rabbits 
at 100 mg/kg/day , mortality , clinical observations, reduced bod y weights and food consumption
in does were associated with increased resorptions and reduced fetal body  weights.  In rats, t he 
maternal no -observed- effect level (NOEL) was 30 mg/kg/day , and the embry o -fetal development 
NOEL was 100 mg/kg/day . In rabbits, the maternal and embry o-fetal developm ent NOEL  was 
30 mg/kg/day .
GS-9876 was negative in the bacterial reverse mutation (Ames) assay , in vitro chromosomal
aberration assay , and in vivo rat micronucleus assay and is therefore considered to be
nongenotoxic. In the in vitro chromosome aberration assay  in human ly mphocy tes, slight, but
statistically  significant increases in the number of poly ploid cells was observed at the highest
GS-9876 dose level evaluated. GS -9876 did not induce structural chromosome breakage when
evaluated in the in vitro assa y. 
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 19 09 January 2017Table 1-1. Margins for GS - 9876 Based on Systemic Exposure Relative to the 
Observed Human Exposure at 20 mg (AUC)
Species Duration RouteNOAEL
(mg/kg/day)AUC 0-24
(
ng•h/mL)aMarginb
Rat Once daily 
x26weeksOral 10 8800/21,800
(male/female)3.1/7.6
(male/female)
Cynomolgus Monkey Once daily 
x39weeksOral 15c8040 2.[ADDRESS_341010] level. Week 4 male and female rat AUC and week 13Cynomolgus monkey AUC
(combined sex)
b Margins of exposure were calculated using predicted 20 mg single dose exposure in humans of 2865 n g•h/mL (extrapolated 
from 30 mg single dose data in study GS-US -379-1372).
c One animal was euthanized moribund during Week 22 at the 15 mg/kg/day dose level.
[IP_ADDRESS]. Nonclinical Drug Metabolism and Pharmacokinetics
GS-9876 exhibits high absorption in rats, dogs and monkey s.Plasma protein binding is moderate 
in all species with the mean free fraction in humans being of 20.4%.
After oral dosing to albino and pi[INVESTIGATOR_14922], [14C]GS -9876- derived radioactivity  was rapi[INVESTIGATOR_2478] y 
distributed to most tissues and concentrations of radioactivity  were below the limit of 
quantitation by  [ADDRESS_341011] levels of radioactivity  were observed in the 
brain, bone, adipose, and testi s. 
Melanin containing tissues exhibited higher concentrations than 
their non -pi[INVESTIGATOR_279366].  Recovery  of radioactivity  was high 
(≥ 97.8%)
and the main route of elimination of GS -9876 was hepatobiliary  with ≤5.1% orally  
dosed radioactivity  found in urine and
69.4% in bile.
In vitro, GS -[ADDRESS_341012] been dosed with GS -9876 in two clinical 
studies.
[IP_ADDRESS]. Completed Clinical Trial
GS-US-
379-1372: This was a first -in-human, Phase 1, single -dose ranging study  of GS -[ADDRESS_341013], and drug-drug 
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 20 09 January 2017interaction potential using a representative acid reducing agent (omeprazole). No risks were 
identified and no grade 3 or 4 AEs were reported. There were no clinicall y significant changes in 
vital signs, phy sical findings, bleeding times, or ECGs. For further information, refer to the 
current IB.
[IP_ADDRESS]. Ongoing Clinical Trials
GS-US-379- 1582: This is a 12 week proof of concept t rial of GS -9876 in patients with RA to 
evaluate efficacy , safet y, tolerability  and PK of GS -
9876.
GS-US-379-1900: This is a single -and multiple -dose Phase 1 study  of GS -9876 in healthy  
volunteers to evaluate the safet y, tolerability , PK and PD of GS -9876. No risks were identified; 
all AEs were Grade 1 in severit y. No dose relationships were observed between GS -9876 and 
any AE. No AE was assessed by  [CONTACT_279378] .There were no 
clinically  significant changes in vital signs, phy sical findings, laboratory  parameters, or ECGs.
1.3. Rationale for T his Study
Renal dy sfunction may  alter the elimination of drugs resulting in PK and subsequently  
pharmacod ynamic changes. Available data indicate the disposition of GS- 9876 is primarily  via 
hepatic metabolism and elimination with minimal excretion expected in urine. In a nonclinical 
ADME study  in rat (AD -379- 2001), 2.7% to 5.1% of the administered radioactivity  was excreted 
in urine. In study  GS
-US-379- 1372 in humans, 0.6% to 4.1% of the dose of GS -9876 was 
excreted unchanged in urine following single oral doses from 2 to 50 mg. However, renal 
impairment may  alter the disposition of hepatically  cleared drugs due to possible changes in 
hepatic/gut drug metabolism, absorption and plasma protein 
binding. Thus, the objective of this 
study  is to investigate the potential for clinicall y relevant alterations in the PK and safety of 
GS-9876 in subjects with renal impairment.
This study  will be conducted in accordance with regulatory guidance and good scientific
practice. This study  will enroll subjects with moderate renal impairment (Cohort 1) with a 
screening estimated creatinine clearance (CL cr) of 30- 59 mL /min using the Cockcroft- Gault 
(C-G) equation for renal function as recommended by  [CONTACT_2165] (FDA) 
and international guidance documents. Data from these subjects will be compared to matched 
subjects with normal renal function (CL cr≥ 90 mL/min). Subjects with severe renal impairment 
(Cohort 2; CL cr15-29 mL/min) will be evaluat ed if supported by  [CONTACT_279379]/or PK data from 
Cohort 1. Should substantial changes in exposure be observed in Cohort 1, these data would 
inform the need for an expanded study  including subjects with lesser degrees of renal 
dysfunction (Cohort 3; 
CL cr60-89 mL/min) .
As renal impairment may be associated with changes in protein binding, a measurement of 
plasma protein binding will be conducted at or near T maxand at another later timepoint following 
GS-[ADDRESS_341014] indicated that GS -9876 was safe and well tolerated following 7 days 
dosing of GS -
9876 15 mg QD, 30 mg QD or 50 mg QD. GS- 9876 doses of 10 mg QD and 30 mg 
QD are currently  under investigation in subjects with rheumatoid arthritis in study  
GS-US-379-1582. Thus a single dose of 20 mg GS - 9876 represents a safe dose that' s clinically  
relevant and allows for potential increase of GS -9876 exposures in subjects with renal 
impairment. Although food (high fat breakfast) only  had minimal impact (reducing C maxby 
13% and delay ing T maxbut no effect on AUC, on GS -9876 PK study  GS-US-379-1372),
GS-[ADDRESS_341015] of renal impairment on GS -9876 PK.
1.5. Risk/Benefit Assessment for the Study
While there is no direct benef it for the subject participating in the renal impairment study  of 
GS-
9876, the risks are considered to be minimal for the following reasons:
GS-9876 has been in a battery  of nonclinical animal studies, and no renal toxicity  was identified. 
GS-9876 has bee n tested in humans as a single ascending dose over a dose range of 2 to 50 mg 
(GS-US-379- 1372) and as a multiple ascending dose over a dose range of 15 to 50 mg 
(GS-US-
379-1900) and no evidence of nephrotoxicity  has been observed. In general GS - [ADDRESS_341016] on renal impairment on 
GS-9876 PK is expected to be limited. Subjects in this study  will receive a single 20 mg dose of 
GS-9876, which is expected to provide a margin of 2.8 -fold to the NOAEL exposure in the 
39-week C ynomolgus monkey toxicology stud y.
Evidence of deterioration in kidney  function in humans can readil y be detected and monito red 
using routine laboratory  tests. For this study , frequent assessments of kidney  function will be 
performed from the collection of both blood and urine samples. While subjects with renal 
impairment will be enrolled, the risk of further kidney  injury  in these subjects should be 
minimized by  [CONTACT_279380]. Further, this study  will enroll subjects with moderate 
renal impairment (Cohort 1) with a screening estimated creatinine clearance (CL cr) of 
30-59 mL/min first . Data from these subjects will be compared to matched subjects with normal 
renal function (CL cr ≥ 90 mL /min). Subjects with severe renal impairment (Cohort 2; 
CL cr15-29 mL/min) will only be evaluated if supported by  [CONTACT_45308] y and/or PK data from Cohort 1. 
There are several potential cau ses of nephropathy  in patients with chronic autoimmune diseases : 
primary  autoimmune attack on the kidney , secondary  renal am yloidosis , drug -related renal 
disease due to necessary  drugs used to treat the primary  autoimmune disease. Kidney  disease and 
GS-[ADDRESS_341017] drugs intended for chronic use . 
The benefit -risk assessment for this study  is favorable.
1.6. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP),
and all applicable regulatory  requirements.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 23 09 January [ZIP_CODE]. OBJECTIVES
The primary  objective of this study  isas follows:
To evaluate the pharmacokinetics (PK) of GS
-9876 in subjects with impaired renal function 
relative to matched healthy  controls.
The secondary  objecti ve of this study  is as follows:
To evaluate the safet y and tolerability  of GS -9876 in subjects with normal and impaired renal 
function.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 24 09 January [ZIP_CODE]. STUDY  DESIGN
3.1. Study Design
This protocol describes a Phase 1, open -label, parallel -group, adaptive, single -dose, multi- center, 
pharmacokinetic stud y in subjects with renal impairment and matched healthy  controls. A 
maximum of 60 subjects using an adaptive design that includes up to 3 enrolled cohorts.
Cohort 1 (Moderate Renal I mpairment): Up to 20 subjects (10 per group, m oderate renal 
impairment and matched healthy  controls) for 8 evaluable subjects per group.
Adaptive Cohort 2 (Severe Renal Impairment): Up to 20 subjects ([ADDRESS_341018]) for 
8 evaluable subjects per group.
Adaptive Cohort 3 (Mild Renal I mpairment): Up to 20 subjects ([ADDRESS_341019]) for 8 evaluable 
subjects per group.
Adaptive Cohorts 2 and/or 3 will be enrolled as determined b y safet y and/or PK data i n Cohort 1. 
Specificall y, Cohort 2 (Severe Renal Impairment) will be evaluated if supported by [CONTACT_45308] y and/or 
PK data from Cohort 1 (Moderate Renal Impairment). Cohort 3 (Mild Renal I mpairment) will be 
evaluated if supported b y safet y and if substantial cha nges ( ≥ 2-fold mean difference from 
matched controls) in the exposure of GS -[ADDRESS_341020] in the control group will 
be matched for age (± 10 y ears), gender, and body mass index (± 20%, 18 kg/m2and 36 
kg/m2).
An overview of t he stud y desi gn is described below and shown in Figure 3-1and Figure 3-2.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 25 09 January 2017Figure 3-1. High Level Schema
;--- ------· ---
' 
Cohort 1 
Mod erate Renal 
Impairment 
0 ,_--- -,;-----------------
1 
0 \ 
I 
0 
------ ---)-: 0 
0 
I Adapt ive Cohort 2 
Seve re Renal 
Impairment 
\ I 
\ ' I 
,;---------------
I ' \ i I 
1 I : Adapti ve Cohort 3 : 
--------? : Mild Renal 
Impairment 
', -------- ----------' 
GS-[ADDRESS_341021] 8 hours (no food or drink except water), stud y drug will be 
administered in the morning with [ADDRESS_341022] until after 
collection of the 4 -hour PK sample, relative to study  drug dosi ng. Additionally , subjects will be 
restricted from water consumption 1 hour before until 2 hours after dosing, except for the 
240mL given with the study  treatment.
Please refer to Section 5.3for additional information for study drug dosage and administra tion.
3.3. Clinic Confinement
Following screening and Day -1procedures, eligible subjects will be confined to the study  center 
beginning Day -1until completion of assessments on Day  6. Subjects will return 14 (± 1) day s
after last dose for an in-clinic follow up visit (ie. Day  15).
3.4. Pharmacokinetic Assessments
Pharmacokinetic assessments will occur on assigned study day s as outlined in Table 6-1and 
Section 6.7.

GS-[ADDRESS_341023]’s last observation (or visit).
GS-[ADDRESS_341024] Selection
A total of u p to 60 subjects will be enrolled in the study (up to 20 subjects per cohort ) , consisting 
of health y male and nonpregnant, nonlactating female subjects of18 through [ADDRESS_341025] within a cohort.
Subjects will comprise those with normal and impaired renal function. Those with impaired renal 
function will be categorized based on estimated creatinine clearance (CL cr) using the 
Cockcroft -Gault (C -G) equation for renal function as recommended by  [CONTACT_33438] (FDA) and international guidance documents. Classification of renal impairment 
is defined as follows:
Mild : CL cr60-89 mL/min
Moderate: CL cr30-59 mL/min
Severe: CL cr15-29 mL/min
Severe renal impairment subjects requiring or anticipated to r
equire dial ysis within [ADDRESS_341026] of matched control subjects with 
normal renal function ( CL cr≥ 90 mL /min).
Each subject in the control group will be matched for age (± 10 y ears), gender, and bo dy mass 
index (± 20%, 18 kg/m2and 36 kg/m2).
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study :
4.2.1. All Subjects
1)Have the ability  to understand and sign a written informed consent form (ICF), which must 
be obtained prior to initiation of study  procedures
2)Be between 18through 75years of age, inclusive at s creening
3)Must be able to comply  with the smoking restrictions at the study  site.
4)Have a calculated body  mass index ( BMI ) of1
8kg/m2and 36kg/m2at screening
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 29 09 January [ZIP_CODE])Females of childbearing potential (as defined in Appendix 3)must have a negative serum 
pregnancy  test at screening and clinic admission ( Day -1).
6)Female subjects must refrain from egg donation and in vitro fertilization during treatment 
and until at least [ADDRESS_341027] dose of study  drug.
7)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 3.
8)
Male subjects must refrain from sperm donation from clinic admission (eg, Day  −1), 
throughout the stud y period, and continuing for at least 90days follow ing the last dose of 
study  drug
9)Subjects have not donated blood within [ADDRESS_341028] dose of study  drug.
10)Have either a normal 12 -
lead ECG or one with abnormalities that are considered clinically  
insignificant b y the investigator in consultation with the sponsor
11)Must be willing and able to comply  with all study  requirements
12) Must, in the opi[INVESTIGATOR_871], be in good health based upon medical history  and 
physical examination, including vital signs
13)Subjects must have the following laboratory  parameters at screening:
a)Hemoglobin ≥ 8.0 g/dL (International S ystem of Units [SI ]: ≥80 g/L)
b)White blood cells ≥3.0 x 103cells/mm3(SI: ≥ 3.0 × 109cells/L )
c)Neutrophils ≥1.5 x 103cells/mm3(SI: ≥ 1.5 × 109cells/L )
d)Lym phocy tes ≥ 0.5 x 103cells/mm3(SI: ≥ 0.5 × 109cells/L )
e)Platelets ≥100 x 103cells/mm3(SI: ≥ 100 × 109cells/L)
f)Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 1.5×ULN
g)Total bilirubin level <
2 ×ULN 
4.2.2. For Subjects with Renal Impairment
Subjects with mild, moderate, or severe renal impairment must also meet the following 
additional inclusion criteria to be eligible for participation in this study :
1)Must have diagnosis of chronic (> 6 months), stable renal impairment with no clinically
significant change in renal function status within 90 day s prior to study  drug administration
(Day  1).
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 30 09 January [ZIP_CODE])Have a creatinine clearance ( CL cr) < 90 mL/min (using the Cockcroft -Gault m ethod 
{Cockcroft et al 1976 }) based on serum creatinine and actual body  weight as measured at 
screening ,ie,
Male: (140 –
Age [years]) (Weight [kg])CL cr(mL/min)
72(Serum Creatinine [mg/dL ])
Female: (140 – Age [years]) (Weight [kg])0.85  CLcr(mL/min)
72(Serum Creatinine [mg/dL ])
Mild : CL cr60-89 mL/min
Moderate: CL cr30-59 mL/min
Severe: CL cr15-29 mL/min
4.2.3. For Healthy 
Matched Controlled Subjects (Subjects with Normal Renal 
Function)
Health y matched control subject must also meet the following additional inclusion criteria to be 
eligible for participation in this study :
1)Must, in the opi[INVESTIGATOR_871], be in good health based upon medical history  and 
physical examination, including vital signs .
2)Have a creatinine clearance ( CL cr) 90mL/min (using the Cockcroft -Gault method 
{Cockcroft et al 1976 }) based on serum creatinine and actual body  weight as measured at 
screening ,ie,
Male: (140 –
Age [years]) (Weight [kg])CL cr(mL/min)
72(Serum Creatinine [mg/dL ])
Female: (140 – Age [years]) (Weight [kg])0.85  CLcr(mL/min)
72(Serum Creatinine [mg/dL ])
3)Match in age (± 10 years), gender, and bod y mass index (± 20%, 18 kg/m2and 36 
kg/m2).
4.3. Exclusion Criteria
4.3.1. All Subjects
Subjects who meet any of the following exclusion criteria will not be enrolled in this study :
1)Bea lactating female
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 31 09 January [ZIP_CODE])Have received an y investigational compound within 30 days prior to study  dosing
3)Have c urrent alcohol or substance abuse judged by  [CONTACT_279381]
4)Have apositive test result for human immunodeficiency  virus type 1 (HIV-1) antibod y, 
hepatitis B surface antigen (HBsAg) ,hepatitis B core antibody (HBc Ab) ,or hepatitis Cvirus
(HCV) antibod y
5)Have poor venous access that limits phlebotomy
6)Have been treated with sy stemic steroids, immunosuppressant therapi[INVESTIGATOR_014], or chemotherapeutic 
agents within 3 months prior to 
screening or is expected to receive these agents during the 
study  (eg, corticosteroids, immunoglobulins, and other immune -or cy tokin e-based therapi[INVESTIGATOR_014])
7)Have a history  of any  of the following:
a)Significant serious skin disease, such as but not limited to rash, food allergy , eczema, 
psoriasis, or urticaria
b)Significant drug sensitivity  or drug allergy  (such as anaphy laxis or hepatoxicity )
c)Known hy persensitivity  to the study  drugs ,their metabolites or to formulation excipi[INVESTIGATOR_840] 
(see Section 5)
d)Significant cardiac disease (incl uding history  of my ocardial infarction based on ECG 
and/or clinical history , any  history  of ventricular tachy cardia, c ongestive heart failure, or 
dilated cardiom yopath y with left ventricular ejection fraction < 40%), a family  history  of 
long QT syndrome , or unexplained death in an otherwise healthy  individual between the 
ages of 1 and 30 years
e)Syncope, palpi[INVESTIGATOR_814], or 
unexplained dizziness
f)Impla nted defibrillator or pacemaker
g)Liver disease, including Gilbert disease
h) Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid 
hypersecretory  conditions requiring prolonged (> 6 months) medical treat ment.
i)Medical or surgical treatment that permanentl y alteredgastric absorption (eg, gastric or 
intestinal surgery ).A history  of cholecy stectom y is not exclusionary. 
j)History  of any  major bleeding event defined as Grade 3 severit y and above (as defined b y
the modified CTCAE 4.03[ Appendix 4]) within the last y ear or personal or family  history  
of bleeding disorder
k)Current use of chronic anticoagulant or anti- platelet agent, not including daily  aspi[INVESTIGATOR_279367].
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 32 09 January [ZIP_CODE])Have an y serious or active medical or ps ychiatric illness (including depression) that, in the 
opi[INVESTIGATOR_2511] i nvestigator, would interfere with subject treatment, assessment, or compliance 
with the protocol. This would include cardiac, hematological, hepatic, pulmonary  (including 
chronic asthma), endocrine (including diabetes), central nervous, gastrointestinal (including 
an ulcer), vascular, metabolic (thy roid disorders, adrenal disease), immunodeficiency  
disorders, active infection, or malignancy  that are clinically  significant or requiring 
treatment.
9) Recent significant changes in the use of nicotine or nicotine containing products 
(ie,initiation, substantial increase or decrease or cessation of use) in the 90 day s prior to 
study drug dosing, or anticipated significant changes in t he use of nicotine or nicotine 
containing products during the course of the study  through the follow -up visit.
4.3.2. For Subjects with Renal Impairment 
1)Require or are anticipated to require dial ysis within 90 day s of study  dosing
2)Require during the study  orhave received moderate or strong inhibitors or inducers of 
CYP3A within [ADDRESS_341029] be approved 
by [CONTACT_24318] (or Clinic al Pharmacologist) prior to study  enrollment 
and study  drug administration.
4.3.3. For Healthy Matched Controlled Subjects (Subjects with Normal Renal 
Function)
1)Have taken an y prescription medications or over -the-counter medications, including herbal 
products andantacids, within 28 days prior to start of study  drug dosing, with the exception 
of vitamins and/or acetaminophen and/or ibuprofen and/or hormonal contraceptive 
medications and/or stable hormone replacement therap y in peri- /post-menopausal females
GS-[ADDRESS_341030], or designee, in an open- label fashion to subjects.
5.2. Description and Handling of GS-9876
5.2.1. Formulation
GS-9876 will be supplied as 10 mg tablets that are round, plain -faced and film -coated blue. Each 
tablet contains 10mg of GS-9876 free base as the succinate form (GS- 9876 -02). The GS-9876 
tablets contain commonly used excipi[INVESTIGATOR_279368], mannitol, 
croscarmellose so dium, magnesium stearate, po lyviny l alcohol, pol yethyleneglycol, titanium 
dioxide, talc, and FD&C blue #
2/indigo carmine aluminum lak e. 
5.2.2. Packaging and Labeling
GS-9876 tablets are packaged in white, h igh-density polyethy l ene (HDPE) bottles. Each bottle 
contains 30 tablets, silica gel desiccant and polyester packing material. Each bottle is enclosed 
with a white, continuous thread, child -resistant poly propy lene screw cap with an 
induction- sealed and alu minum -faced liner.
Study  drug(s) to be distributed to centers in the US and other participating countries willbe 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), European Union ( EU)Guideline to Good Manufac turing Practice – Annex 13 
(Investigational Medicinal Products), and/or other local regulations.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 34 09 January [ZIP_CODE].2.3. Storage and Handling
GS-9876 tablets should be stored at controlled room temperature of 25 ºC (77 ºF); excursions are 
permitted between 15 ºC and 30 ºC (59 ºF and 86 ºF). Storage conditions are specified on the 
label. 
Until dispensed to the subjects, all drug products should be stored in a securely  locked area, 
accessible only  to authorized site personnel. To ensure the stability  of the study  drugs and to 
ensur e proper product identification, the drug products should not be stored in a container other 
than the containers in which they  are supplied. Consideration should be given to handling, 
preparation, and disposal through measures that minimize drug contact [CONTACT_279382] . 
Appropriate precautions should be followed to avoid direct ey e contact [CONTACT_279383].
5.3. Dosage and Administration of Study Drug
Following completion of Screening and Day  -1 assessments, eligible subjects will be enrolled in 
1 of the 3 cohorts and receive a single oral dose of GS
-9876 20 mg ( 2 × 10 mg tablet) in a fasted 
state on Day  1.
5.4. Fasting and Meals
Study  drug will be administered in the morning with [ADDRESS_341031] until after collection of the 4 -hour PK sample, relative to study  drug dosing. Additionally , 
subjects will be restricted from water consumption 1 hour before and2 hours after dosing, except 
for the 240 mL given with the study drug.Water may  be freel y consumed following the 2- hour 
blood draw and for the remainder of the collection period. 
All meals and/or snacks given to subjects during their stay  in the clinical study  facility  will be 
standardized for all subjects and should be similar in calorie and fat content and taken at 
approximat ely the same time each day . All meals provided must be approved by  [CONTACT_456].
Components of meals (eg, margarine, jelly , bread) should be given to subjects in individual 
portions (eg, 1 tablespoon) per the approved meal schedule. The provision of meal co mponents 
in bulk (eg, a jar of jelly  for subjects to share) should not be practiced. All meals should be given 
at approximately  the same time each day  (eg, 07:30, 12:00, and 18:00).
5.5. Accountability forStudy Drug
The investigator is responsible for ensuring adequate accountability  of all used and unused study  
drug bottles. This includes acknowledgement of receipt of each shipment of study  drug (quantity  
and condition). All used and unused study  drug bottles dispensed to subjects must be returned to 
the site.
Study  drug accountability  records will be provided to each study  site to:
Record the date received and quantity  of study  drug bottles
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 35 09 January 2017Record the date, subject number, subject initials, and the study  drug bottle number dispensed
Record the date, quantity of used and unused study drug tablets returned, along with the 
initials of the person recording the information.
5.5.1. Investigational Medicinal Product Return or Disposal
Please refer to Section 9.1.7
5.6. Concomitant Medications and Other Protocol Restrictions
5.6.1. Concomitant Medications
[IP_ADDRESS]. Subjects with Normal Renal Function
The following medications are excluded while subjects are participating in the study (from 
screening until discharge) . This list does not include medications such as anti -HIV agents that 
would be contraindicated for other exclusion criteria.
Any prescription medications and over -the-counter medications, including herbal products 
and antacids ,with the exception of vitamins, and/or acetaminophen and/or ibuprofen and/or 
hormonal contraceptive medicat ions and/or stable hormone replacement therap y in 
peri- /post-menopausal females. However, the short- term use of topi[INVESTIGATOR_210133] A D ointment to treat minor skin irritation due to ECG leads will be allowed. If a 
subject requires use of a d isallowed medication, a request for such use must be reviewed b y 
the sponsor and if approved, subjects may  continue to participate in the study .
Any and all illegal or illicit drug use , including use of prescription drugs outside the care of 
the prescribin g physician.
[IP_ADDRESS]. Subjects with Renal Impairment 
Concomitant use of certain medications or herbal/natural supplements with study  drug may  result 
in PK interactions resulting in increases or decreases in exposure of study  drug or these 
medications.
Concomitant medications taken within 30 day s of Screening through the follow -up visi t need to 
be recorded in the source documents and electronic Case Report Forms (eCRFs).
The following medications are excluded while subjects are participating in the study (from 
screening until discharge) .This list does not include medications such as anti -HIV agents that 
would be contraindicated for other exclusion criteria.
Any and all illegal or illicit drug use , including use of prescription drugs outside the care of 
the pres cribing ph ysician.
Current alcohol or substance abuse judged b y the Investigator to potentiall y interfere with
subject compliance (eg. amphetamines, cocaine, opi[INVESTIGATOR_858]).
Moderate or strong CYP3A4 inhibitors or inducers within 2 weeks prior to study  drug 
admi nistration and through the follow up visit.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 36 09 January 2017Concurrent therap y with any anti -coagulant (eg, coumadin [warfarin], any  Vitamin K
antagonist, any  novel oral anticoagulant, any  heparin or low molecular heparins, inhibitors of 
factor Xa)
Concurrent therap y with any anti- platelet therap y (eg, adenosine diphosphate [ADP] receptor
inhibitors, phosphodiesterase inhibitors, PAR- 1 antagonists, Gl ycoprotein 2b/3a inhibitors)
with the exception of ≤ 100 mg daily of aspi[INVESTIGATOR_279369]
Subjects with renal impairment with co-morbid diseases requiring medication(s) must be 
taking the medication(s) without a change in dose for > [ADDRESS_341032] be approved 
by [CONTACT_117128] d Medical Monitor (or the Clinical Pharmacologist) prior to study  
enrollment and study  drug administration.
Table 5-1includes examples of prohibited medicines in subjects with renal impairment.
Table 5-1. Examples of Prohibited Medications for Subjects with Renal 
Impairment
Drug Class Agents Disallowed
Strong CYP3A4 Inhibitorsaclarithromycin, conivaptan, itraconazole, ketoconazole, nefazodone, 
posaconazole, telithromycin, voriconazole, telaprevir, boceprevir, grapefruit 
juice, idelalisib, Viekira Pak ( ombitasvir, pari taprevir, ritonavir, d asabuvir ), 
troleandomycin , mibefradil
Strong CYP3A4 Inducersbcarbamazepi[INVESTIGATOR_050], phenytoin, rifampin, fosphenytoin, pentobarbital, primidone, 
rifabutin, rifapentine, phenobarbital, mitotane, avasimibe, St. John’s Wort, 
enzalutamide
Moderate CYP3A4 Inhibitorsafluconazole, erythromycin, diltiazem, dronedarone, aprepi[INVESTIGATOR_053], casopi[INVESTIGATOR_053], 
imatinib, verapamil, tofisopam, ciprofloxacin, cimetidine, cyclosporine, 
Schisandra sp henanthera, crizotinib, netupi[INVESTIGATOR_053], nilotinib, isavuconazole
Moderate CYP3A4 Inducersbbosentan, thioridazine, nafcillin, modafinil, semagacestat, genistein
Anti-plateletcadenosine diphosphate (ADP) receptor inhibitors, phosphodiesterase 
inhibitors, PAR -1 antagonists, Glycoprotein 2b/3a inhibitors
Anti-coagulant warfarin, any Vitamin K antagonist, any novel oral anticoagulant, any heparin 
or low  molecular heparins, inhibitors of factor Xa
a In vitro data indicate GS-[ADDRESS_341033] is on study drug and 2 weeks prior to study drug administration.
c ≤ 100 mg aspi[INVESTIGATOR_279370] 
5.6.2. Other Protocol Restrictions
Subjects will be required to refrain from the consumption of food and beverages containing 
alcohol products [ADDRESS_341034] dose of study  drug and during the course of the 
study  through the follow- up visit.
Subjects must be able to comply  with t he smoking restrictions at the study  site.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 37 09 January 2017Subjects will be required torefrain from consumption of grapefruit juice, grapefruits, and 
Seville orange juice 96hours prior to the first dose of study  drug and during the course of the 
study  through the follow -up visit.
While confined at the study  center, tea, coffee, chocolate, and other foods and beverages 
containing caffeine and other methy l xanthines will be prohibited on each dosing day . Atall 
other times, caffeine -containing beverages and foodstuff s may  be served or withheld in 
accordance with normal study  center practice. Caffeine -containing beverages and foodstuffs 
will not be restricted while subjects are outside of the clinic.
Subjects will be encouraged to avoid strenuous or prolonged exercise, as well as saunas, 
steambaths, and sunbathing or oth er prolonged ultraviolet exposure, eg, in a tanning salon, 
from the 
screening evaluation until completion of the follow -up visit, as these activities are 
known to affect certain clinical laboratory test parameters, (eg,creatine kinase ) and will 
provide false indicators of a potentially  treatment -related toxicity . 
Upon every admission to the clinic, each subject will be questioned as to their compliance with 
the above protocol restrictions. If a subject is unable to comply  with an y of the restrictions 
described above, the subject’s continued participation in the study  will be reevaluated by  [CONTACT_122034] s ponsor.
GS-[ADDRESS_341035]’s clinical chart and 
appropriate electronic case report f orms ( eCRFs ). In addition, the sponsor should be promptly  
notified of an y protoc ol deviations. 
The study  center will not initiate dosing until the following have all been met :
The institutional review board (IRB)/ ethics committee ( EC)/other applicable regulatory  
agencies have reviewed and approved the study  and the informed consent document
.
All requested regulatory  documents have been submitted to and approved by  [CONTACT_10866] .
A master services agreement and/or study 
agreement is executed.
The study  initiation meeting has been conducted by  [CONTACT_90269] (or designee).
The initiation meeting will include but is not limited to a review of the protocol, the IB, study  
drugs, and investigator responsibilities.
Documentation of the personally  signed and dated ICFforeach subject, using the stud y
-specific ,
IRB/EC -approved ICF, is required before initiating the screening process. 
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the investigator to ensure that subjects are eligib le to participate in the 
study  prior to enrollment and continue to remain eligible throughout the study .
Once the ICFhas been obtained, all screening and admission tests and assessments have been 
assessed, and stud y eligibility  has been confirmed, subjects will be enrolled to receive stud y drug 
on Day  1.
Subjects will receive the study treatments as described in Section 5.3.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 39 09 January 2017Table 6-1. Schedule of Assessments
Study Procedure ScreenaDay −
1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6bDay 15(±1)
Follow -UpcETd
Written Informed Consent X
Medical History X
Com plete Physical Exam X X X X X
Symptom -Driven Physical 
ExaminationeX X X X X
Height X
Weight X X
Vital SignsfX X X X X X X X X X
HIV-1, HBV, and HCV 
TestingX
Hem atologygX X X X X X X
Coagulation X X X X X X X
ChemistryhX X X X X X X X
Urinalysis X X X X X X X X
Serum Pregnancy TestiX X X X X
Creatinine Clearance X X
Urine Drug and Alcohol 
Screen X X
12-Lead ECG X X X X X X
Study Drug Administration X
Intensive Plasma PKjX X X X X X
Urine PKkX X X X X X
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 40 09 January 2017Study Procedure ScreenaDay −1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6bDay 15(±1)
Follow -UpcETd
Revie w Study Restrictions X X X X
Clinic Confinement X X X X X X
Revie w AEs & 
Concomitant MedicationslX X X X X X X X X X
a Prospective subjects should be screened no more than 28days prior to administration of the first dose of study drug.
b Subjects will be discharged from the clinic on Day 6 ,following all morning assessments.
c 14(± 1) days after the last administration of study drug , all subjects will return for an in - clinic follow -up visit and complete procedures as outlines .
d Assessments will be p erformed within 72 hours of early termination from the study.
e Symptom -driven PEs will be performed during confinement as needed, based on reported signs and symptoms.
f Vital signs include blood pressure, heart rate, respi[INVESTIGATOR_1487], and temperature .
g Hematology: CBC with differential .
h See Section 6.9.5 for specifics.
i Females of child -bearing potential only.
j Intensive PK sampling will occur relative to the morning dosing of GS-9876 at the following time points:
Day 1: 0 (predose ), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96 and 120 hours postdose.
k All urine voided will be collected and pooled relative to dosing of GS -9876 at the following collection intervals:
Day 1: Predose void, 0-6, 6-12, 12-24, 24-48, 48-72, 72- 96, and [ADDRESS_341036] (no food or drink, except water ), startin g from midnight 
(
00:00) or earlier, as appropriate, on the evening prior to the s creening visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection the next morning.
Written informed consent must be obtained from each subject b efore initiation of anyscreening 
procedure. After a subject has provided informed consent, the i nvestigator and other study  
personnel will determine if the subject is eligible for participation in the study. This assessment 
will include a review of the in clusion/exclusion criteria and completion of all screening 
procedures as outlined in Table 6-1and described in the following text. 
Eligible subjects meeting all of the inclusion criteria and none of the exclusion criteria will be 
instructed on all protoc ol requirements
,including the restrictions on concomitant medication 
usage and other substances as well as consumption of food or beverages containing alcohol, 
caffeine, or xanthine. Subjects will be asked to arrive at the stud y center on Day  -1for admis sion 
assessments.
6.2.2. Admission Assessments
[IP_ADDRESS]. Admission
Subjects should be instructed to fast (no food or drink, except water), starting from midnight 
(00:00) or earlier, as appropriate, on the evening prior to the screening visit to ensure an 
approximate 8-hour fast prior to the fasted blood sample collection.
Subjects meeting all eligibility  criteria following the screening evaluation will return to the clinic 
for admission assessments on Day  -1. The admission evaluations and/or procedures are outlined 
inTable 6-1.
Prior to dosing on Day 1, the results of the clinical and laboratory evaluations (as described in 
Table 6-1must be reviewed by  [CONTACT_941] i nvestigator to confirm the continued eligibility  of each 
subject to participate in the study . At the time of enrollment , subjects will be assigned a 
sequential subject number as described i n Section 5.1.Subjects will remain confined to the study  
clinic for the duration as described in 
Section [IP_ADDRESS] and Table 6-1.
GS-[ADDRESS_341037] number and receive study  treatments as shown in Section 5.3.
6.4. Treatment Assessments
Study  p
rocedures and assessments are outlined in Table 6-1.
6.5. Posttreatment Assessments
All subjects will r eturn 14 days (
±1) after last dose of study  drug for an in-clinic follow- up visit.
Study  procedures and assessments are outlined in Table 6-1.
6.6.
Assessments for Premature Discontinuation from Study
If a subject discontinues study  treatment dosing, for example as a result of an AE, every  attempt 
should be made to keep the subject in the study  and continue to perform the required 
study -related procedures until stab
ilization per the investigator . If this is not possible or 
acceptable to the subject or investigator, the subject may  be withdrawn from the study . 
Evaluations indicating abnormal results believed to be possibly  or probabl y related to stud y 
treatment at the ETvisit should be repeated weekly  or as often as deemed appropriate by  [CONTACT_279384], returns to baseline visit levels, or is otherwise 
explained.
If the subject withdraws from the study , the 
ET evaluations and/or procedures outlined in 
Table 6-1should be performed within 72 hours of permanentl y discontinuing the stud y drug.
6.7. Criteria for Discontinuation of Study
Study  confinement may be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree
Unacceptable toxicity , as defined in the toxicity  managem ent section of the protocol, or 
toxicity  that, in the judgment of the investigator, compromises the ability  to continue study -
specific procedures or is considered not to be in the subject
’s best interest
Subject request to discontinue for an y reason
Subjec t noncompliance
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 43 09 January 2017Pregnancy  during the study  (refer to Appendix 3)
Investigator discretion
Discontinuation of the study  at the request of [COMPANY_009], regulatory  agency , or an I RB/EC
6.8. Pharmacokinetic 
Assessments
6.8.1. Plasma PKCollection
Plasma concentrations of GS-9876 will be determined and PK parameters estimated. Plasma 
concentrations of GS-9876 metabolites may  be determined, if necessary . Intensive PK sampling 
will occur relative to the morning dose of GS-9876 at the following time points:
Intensive PK sampling will occur relative to dosing of GS- 9876 at the following time points:
Day 1: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96 and 120 hours postdose
Protein binding of GS -9876 (and its metabolites, as applicable) will be asse ssed at or near their 
Tmaxtimepoint(s) as well as another later time point.
6.8.2. Urine Pharmacokinetic Collection
Allurine voided will be collected and pooled relative to dosing of GS -9876 at the following 
collection intervals:
Day 1: Pre- dose void, 0-6, 6-12 , 12-24, 24-48, 48-72, 72 -96 and 96- 120 hours postdose
Urine concentrations of GS -9876 and/or metabolites may  be determined and PK parameters 
estimated.
6.9. Safety Assessments
Safety  will be evaluated throughout the study . Refer to Table 6-1for a schedule of assessments.
6.9.1. Electrocardiogram Assessment
Subjects should rest quietly  in the supi[INVESTIGATOR_19636] a minimum of 10 minutes prior to each 
scheduled ECG acquisition and should remain in that position until the recording is complete.
There should be no environ mental distractions (including TV, radio, video games, and 
conversation) while the subjects are resting prior to and during the recordings. 
Electrocardiograms will be recorded using the site’s standard ECG equipment . All ECGs will be 
obtained using instruments that analy ze data using the same algorithms and produce the same 
data for interpretation. Electrode placement will be performed according to the method of 
Wilson, Goldberger, and Einthoven with a check to confirm that the aVR lead is not invert ed.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 44 09 January 2017The investigator or other qualified individuals at the study  center will review ECGs to assess for 
changes in ECG intervals and morphology  as compared with pretreatment ECGs. ECG interval 
measurements output b y the machine will be used for bedside safe ty monitoring.
Collection of additional ECGs for routine safet y monitoring at additional time points or day s is at 
the discretion of the investigator based on GCP .
6.9.2. Physical Examination
Physical examinations conducted throughout the study  will be a complete physical examination 
or a s ymptom -directed phy sical examination ,as outlined in Table 6-1. The complete phy sical 
examination conducted at 
screening will also include the following assessments:
A complete ph ysical examination must include source documentat ion of general 
appearance, and the following bod y systems: head, neck, thy roid; ey es, ears nose, throat, 
mouth and tongue; chest (excluding breasts); respi[INVESTIGATOR_696]; cardiovascular; lymph nodes, 
abdomen; skin, hair, nails; musculoskeletal; neurological.
Revie w medical history , including history  of allergies, prior and current use of nicotine or 
nicotine -containing products, alcohol and illegal drug use ,and prior (within 30 day s) and 
current medication use .
6.9.3. Vital Signs
Vital sign measurements include blood pre ssure, heart rate , respi[INVESTIGATOR_1487], and temperature and 
should be taken once subjects have been seated or in the supi[INVESTIGATOR_19636] a minimum of 
5-[ADDRESS_341038] p osition for measurement should be kept consistent throughout the stud y. 
Refer to Table 6-1forvital signs collection time points.
6.9.4. Body Mass Index
Height and weight will be collected at screening for calculation of BMI for inclusion criteria.
6.9.5. Clinical Laboratory Tests/Assessments
Blood and urine samples for safety  evaluations will be collec ted throughout the study  as outlined 
in Table 6-1.
[IP_ADDRESS]. Blood 
Sampling
Blood samples will be collected for the following laboratory  anal yses:
Hematology : Hematocrit, hemoglobin, platelet count, red blood cell (RBC) count , white 
blood cell(WBC) count with differential (absolute and percentage) ,including lymphocy tes, 
monocy tes, 
neutrophils, e osinophils, basophils, and mean corpuscular volume (MCV) 
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 45 09 January 2017Coagulation panel : D-Dimer, prothrombin time (PT), activated partial thromboplastin time 
(aPTT)and internation al normalized ratio (INR)
Chemistry  (fasting): alkaline phosphatase, AST, AL T, total bilirubin, direct and indirect 
bilirubin, total cholesterol, high -densit y lipoprotein (HDL), low -density  lipoprotein (LDL), 
triglycerides, total protein, albumin, lactic a cid dehy drogenase (LDH), creatine 
phosphokinase (CPK), bicarbonate, blood urea nitrogen (BUN), calcium, chloride, creatinine 
(see below), glucose, phosphorus, magnesium, potassium, sodium, uric acid, and am ylase 
(reflex lipase testing is performed in subje cts with total amy lase > 1.5 × upper limit of 
normal [ ULN
] )
Serum pregnancy  test (females of childbearing potential only )
HIV-1, HBV (HbsAg and HBc Ab), and HCV testing ( screening only )
[IP_ADDRESS]. Urine Samples
Urine samples will be col
lected for urinal ysis and alcohol and drug screen assessments.
6.9.6. Creatinine Clearance and Estimated Glomerular Filtration Rate 
Weight will be collected at screening and upon admission to calculate creatinine clearance ( CL cr) 
and estimate glomerular filtration rate (eGFR) , however CL crwill be used for inclusion criteria.
eGFR (mL/min/1.73 m2) =175× (*S cr)-1.154× (Age)-0.203× (0.742 if female) × (1.212 if African 
American)
*Scr–serum creatinine
6.9.7. Adverse Events/Concomitant Medications/Protocol Restrictions
Evaluation for AEs, review of concomitant medications, and review of protocol restrictions will 
occur at the times shown in Table 6-1. See Section 7for more information regarding AEs and 
Sections 4.3and5.6.[ADDRESS_341039] a causal relationship with the treatment. An AE can ,therefore ,
be an y unfavorable and/or unintended sign, s ymptom, or disease temporally  associated with the 
use of a study  drug , whether or not considered re lated to the study  drug . Adverse events may also 
include pre -or posttreatment complications that occur as a res ult of 
protocol -specified
procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or occupational exposure .
Preexisting events that increase in severity or change in nature during or as a consequence of 
participation in the clinical study  will a lso be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, and transfusion. 
The condition that ledto the procedure may  be an AEand must be reported.
Preexisting diseases, cond itions ,or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (eg ,hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.4)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and that is not related to a protocol- associated procedure is 
not an AE. It is considered to be pre existing and should be documented on the medical 
history  eCRF.
7.1.2. Serious Adverse Events
A SAE is defined as 
an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
Inpatient hospi[INVESTIGATOR_279371]-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 47 09 January 2017Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction ;such events may  not be immediately  
life-threatening or result in death or hospi[INVESTIGATOR_82221]. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically  important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities 
and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , urinaly sis) that require 
medical or surgical intervention or lead to study  drug interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, ECG , x-rays, vital signs) that are associated with 
signs and/or s ymptoms must be recorded as an AE or SAE if they  meet the definition of an AE 
or SAE as described in Sections 7.1.[ADDRESS_341040] the s yndrome or diagnosis (eg, anemia), not the laboratory  result (ie, decreased 
hemoglobin).
For specific inf ormation on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5.
7.2. Assessment of Adverse Events and Serious Adverse Events
The i
nvestigator or qualified s ubinvestigator is responsible for assessing AEs and SAEs for 
causal ity and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to study  
drug using clinical judgment and the following considerations:
No: Evidence exists that the AEhas an etiology  other than the study  drug. For SAEs, an 
alternative caus
ality must be provided (eg, pre existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_24384] .
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 48 09 January 2017It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of AE reporting . 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the AE has an etiology  other than the study  procedure.
Yes: The AEoccurred as a result of protocol procedures (eg,venipun
cture) .
7.2.2. Assessment of Severity
The severit y grading of AEs will be assessed as Grade 1, 2, 3 , 4or 5using the Common 
Terminology  Criteria for Adverse Events (CTCAE) version 4.03. For AEs associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may  not be in agreement with the grading of 
the laboratory abnormality . 
The only  modification to the CTCAE criteria is the addition of a Grade 1 upper respi[INVESTIGATOR_696] , as 
described in Appendix 4.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
7.3.1. Requirements for C ollection Prior to Study D rug Initiation:
After obtaining informed consent, but prior to initiation of study  drug , all SAEs and AEs related 
to protocol -mandated procedures should be reported on the eCRF .
[IP_ADDRESS]. Adverse Events
Following initiation of study  treatment , collect a ll AE s, regardless of cause or relationship, until 
[ADDRESS_341041] tha t certain AEs be followed bey ond the protocol -defined follow -up period.
[IP_ADDRESS]. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (ie, signing the informed consent) and th
roughout the duration of the 
study , including the protocol -required posttreatment follow -up period, must be reported to the 
eCRF database and [COMPANY_009] DSPH as instructed. This also includes any  SAEs resulting from 
protocol -associated procedures performed after informed consent is signed.
GS-[ADDRESS_341042] dose of study  drug, regardless of causalit y, should also be reported.
Investigators are not obligated to activel y seek SAEs after the protocol -defined follow -up perio d;
however, if aninvestigator learns of any  SAEs that occur after stud y participation has concluded 
and the 
event is deemed relevant to the use of study  drug , the investigator should promptly  
document and report the event to [COMPANY_009] DSPH.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline
.
[IP_ADDRESS]. Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF databa se and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions may be found in the eCRF completion guidelines.
If for a ny reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning record the SAE on the paper serious adverse event reporting form 
and submit within 24 hours to:
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF databa se has been locked, no 
further action is necessary.
For fatal or life -threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are alsoto be submitted by [CONTACT_82234]. 
Transmission of su ch doc uments should occur without personal subject identification, 
maintaining the tra ceability  of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessar y for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form.
7.4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable [LOCATION_002] 
(US)FDA Code of Federal Regulations, the European Union ( EU)Clinical Trials Directive [COMPANY_009] DSPH Email: 
Fax: 
[COMPANY_003]
[COMPANY_003]
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 50 09 January 2017(2001/20/EC) and relevant updates, and other country -specific legislation or regulations, [COMPANY_009] 
may berequired to expedite to w orldwide regulatory  agencies reports of SAEs , serious adverse 
drug reactions (SADRs) ,or S[LOCATION_003]Rs .In accordance with the EU Clinical Trials Directive 
(2001/20/EC), [COMPANY_009] or a specified designee will notify  worldwide regulatory  agencies and the 
relevant independent e thics committee ( IEC)in concerned member s tates of applicable S[LOCATION_003]Rs
as outlined in current regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_279385]. 
All investigator s will receive a safet y letter notifying them of relevant S[LOCATION_003]R reports associated 
with any  study  drug . The investigator should notify  the IRB or IEC of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in acco rdance with the local 
institutional policy . 
7.5. Toxicity Management 
Treatment -emergent toxicities will be noted by [CONTACT_204977], who will have a discussion with the investigator and 
decide the appropriate course of action. Whether or not considered treatment -related, all subjects 
experiencing AEs must be monitored periodically  until sy mptoms subside, any  abnormal 
laboratory  values have resolved or returned to baseline levels or they  are c onsidered irreversible, 
or until there is a satisfactory  explanation for the changes observed.
Grade 3 or 4 clinicall y significant laboratory abnormalities should be managed as outlined in 
Appendix 2.
Severity  should be recorded and graded according to the
modified CTCAE Grading Scale as 
described in ( Appendix 4). 
For adverse events associated with laboratory
 abnormalities, the event should be graded on the 
basis of the clinical severity  in the context of the underly ing conditions; this may  or may  not be 
in agreement with the grading of the laboratory  abnormality .
Any questions regarding toxicity  management should be directed to the [COMPANY_009] Sciences 
Medical Monitor.
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports inclu de all reports of medication error, abuse, misuse, overdose,
occupational exposure with an AE, AE in an infant following exposure from breastfeeding, 
reports of AEs associated with product complaints, and pregnancy  reports regardless of an 
associated AE.  
GS-[ADDRESS_341043] labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subje ct cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Occupational exposure is the exposure to a medicinal product as a result of one's professional or 
non-professional occupation.
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.   
7.6.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnan cies
The investigator should report pregnancies in female study  subjects 
that are identified after 
initiation of study  drug and throughout the stud y, including the poststud y drug follow -up period, 
to [COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming aware of the 
pregnancy . 
Refer to the eCRF completion guidelines for full instructions on the mechanism of pregnancy 
reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  withou t medical reasons.
Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons
) must be reported within [ADDRESS_341044] should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the ou tcome should be reported directl y to [COMPANY_009] DSPH by  [CONTACT_279386] 3, Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
[IP_ADDRESS]. Reporting Other Speci al Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] DSPH within [ADDRESS_341045] o
f situations that involve study drug and/or [COMPANY_009] concomitant 
medications but do not apply to non- [COMPANY_009] concomitant medications. 
Special situations involving non -[COMPANY_009] concomitant medications does not need to be reported on 
the special situations report form; however, for speci al situations that result in AEs due to a 
non-[COMPANY_009] concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by
 [CONTACT_10857] “misuse” but may  be more appropri ately  documented as a protocol deviation.
Refer to S ection 7.6.2 and the eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reporte d as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 53 09 January [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Obje ctives
The primary  objective of this study  is as follows:
To evaluate the PK of GS-9876 in subjects with impaired renal function relative to matched, 
healthy  controls
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerabil ity of GS-[ADDRESS_341046], AUC inf, and C maxfor GS -9876.
8.1.3. Secondary Endpoint
The secondary  endpoints include incidences of AEs, laboratory  abnormalitie s, abnormal findings 
in vital signs and safety  ECG monitoring.
8.2. Analysis Conventions
8.2.1. Analysis 
Sets
[IP_ADDRESS]. All Enrolled
The All Enrolled Anal ysis Set includes all subjects enrolled into the study  after screening. This is 
primary  anal ysis set for listings.
[IP_ADDRESS]. Safety
The Safet y Analysis Set will include all enrolled subjects who received 1dose of GS-9876 . 
[IP_ADDRESS]. Pharmacokinetics
The PK Anal ysis Set will include all enrolled subjects who received [ADDRESS_341047] 1nonmissing PK concentration datumreported by [CONTACT_279387]. 
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 54 09 January [ZIP_CODE].3. Data Handling Conventions
For summary  statistics, PK concentration values below the limit of quantitation ( BLQ ) will be 
treated as zero at predose and 1-half of the lower limit of quantitation (LLOQ) for postdose time 
points.
Laboratory  data that are continuous in nature but are less than the LLOQ or above the upper limit 
of quantitation will be imputed to the value of the lower or upper limit minus or plus
1signi ficant digit, respectively  (eg, if the result of a continuous laboratory  test is <20, a value of 
19 will be assigned
; if the result of a continuous laboratory  test is < 20.0, a value of 19.9 will be 
assigned).
Missing data can have an impact upon the interpretation of the study data. As this study  is of 
short duration, it is antici pated that missing data will be minimal. I n general, values for missing 
data will not be imputed. However, a missing pretreatment laboratory  resul t would be treated as 
normal (i e, no toxicity  grade) for the laboratory  abnormality  summary .
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be su mmarized and descriptive statistics will be 
provided.
Demographic summaries will include sex, race/ethnicity , enrollment , and age.
8.5.
Interim Analysis
Review of available safety  and PK data will be conducted by  [CONTACT_279388].
8.6. Safety Analysis
All safet y data collected on or after the date that study drug was first administered up to the date 
of last dose of study drug plus [ADDRESS_341048]’s extent of exposure to study  drug data will be generated from the study  drug
administration page in eCRF. Exposure data will be listed.
8.6.2. Adverse Events
Clinical and laboratory  AEs will be coded using the Medical Dictionary  for Regulatory  
Activities (MedDRA). Sy stem organ class (SOC), high-level group term (HLGT), high-level 
term (HLT), preferred 
term(PT), and lower -level term (LLT) will be attached to th e clinical 
database.
GS-[ADDRESS_341049]. Treatment -emergent AE s(TEAE s), serious TEAE s, 
and TEAEs leading to discontinuation of treatment will be summarized by  [CONTACT_3148], SOC , and 
PTusing the current version of MedDRA. 
8.6.3. Laboratory Evaluations
Listings of individual subject laboratory  results will be provided. Laboratory  results and change 
from predose values for selected lab tests will be summarized by  [CONTACT_279389]. The incidence of treatment -
emergent g raded laboratory  abnormalities will be 
summarized by  [CONTACT_3148].
8.6.4. Other Safety Evaluations
Vital signs and ECG data will be summarized by  [CONTACT_210141] .
8.7. Pharmacokinetic Analysis
Plasma concentrations and PKparameters for GS-9876 will be listed and summarized by [CONTACT_279390] ( eg, sample size, mean, SD, % coefficient of variation , 
median, first quartile [Q1], third quartile [Q3], minimum, and maximum).
In addition, an anal ysis of variance approp riate for a parallel design will be fitted to the natural 
logarithmic transformation of PK parameters (AUClast, AUC inf,and Cmax) f or GS-9876 . 
Two-sided 90% CIs will be calculated for the GLSM ratios of PK parameters between renal 
impairment group versus the control (normal renal function) group.
If determined, urine concentrations of GS- 9876 over sampling time will be listed and 
summarized by  [CONTACT_279391]. Urine concentration s ver s us time 
profiles of GS -9876 and its m etabolites (if applicable) may be display ed by [CONTACT_210141], 
as appropriate. When possible, urinary  PK parameters (Ae, CLr and % Dose excreted ) will be 
calculated.
Protein binding of GS -9876 in plasma (at or near T maxand a later timepoint) will als o be 
summarized by  [CONTACT_279391].
The PK of GS -
9876 metabolites (if applicable) may  also be evaluated.
8.8. Sample Size
With 16 (8 per group) evaluable subjects, the estimated two- sided 90% CI of the GL SM ratio of 
test versus reference groups, with regards to PK parameters (AUC and Cmax) would be within 
(50%, 200%) with over 95% probability . This calculation is based on a two group t -test of 
equivalence in means at the significance level of 0.05, assuming the expected geometri c means 
ratio of 1.[ADDRESS_341050] dose levels (15 mg and 
30mg) of the dose in this study . An overage of [ADDRESS_341051] drop- outs, thus requiring a total enrollment of 20 subjects (10 per group) 
for each cohort .
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 56 09 January [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and South 
Africa), International Conferen ce on Harmoni zation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent with the EUClinical Trials 
Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice (GCP) , 
as outlined in 21 Code of Federal Regulations ( CFR) 312, S ubpart D, “Responsibilities of 
Sponsors and Investigators,” 21 CFR, P art50, "Protection of Human Subjects ,"and 21 CFR, 
Part56, "Institutional Review Boards . "
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 
"Financial Disclosure b y Clinical I nvestigators, " providing documentation of their financial 
interest or arrangements with [COMPANY_009], or proprietary interests in the study drug under study . This 
documentation must be provided prior to the investigator’s (and an y subinvestigator’s) 
participation in the study . The investigator and subinvestigator agree to notify  [COMPANY_009] of any  
change in reportable interests during the study  and for [ADDRESS_341052]/Independent Ethics Committee Review and 
Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, ICF, and any  accompan ying material to be provided to the subject (such as 
advertisements, subject information sheets, or descriptions of the study  used to obtain informed 
consent) to an IRB/EC . The investigator will not begin an y study subject activities until approval 
from the IRB/EC has been documented and provided a s a letter to the investigator.
Before implementation, the 
investigator will submit to and receive documented approval from 
the IRB/EC any modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/EC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
GS-[ADDRESS_341053]’s 
legally  authorized representative and the person conducting the consent discussion, and also by  
[CONTACT_279392]/EC local requirements. 
9.1.4. Confidentiality
The investigator must assur e that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed b y local law) ,and an identification code will be recorded on any  
form or biological sample submitted to the sponsor, IRB/EC , or laboratory . Laboratory  
specimens must be labeled in such a way as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to specific laborato ry instructions or in accordance 
with local regulations. NOTE: The investigator must keep a screening log showing codes, names, 
and addresses for all subjects screened and for all subjects enrolled in the study . Subject data will 
be processed in accordance with all applicable regulations. 
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
IB, this protocol, eCRF, the study  drug , and any  other study  information, remain the sole and 
exclusive property  of [COMPANY_009] during the conduct of the study  and thereafter. This information is 
not to be disclosed to any third party  (except employ ees or agents directl y involved in the 
conduct of t he stud y or as required b y law) without prior written consent from [COMPANY_009]. The 
investigator further agrees to take all reasonable precautions to prevent the disclosure by  [CONTACT_279393] y third party or otherwise into the publ ic domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following 2 categories: (1)investigator’s study file and (2) subject 
clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF, IRB/EC and 
governmental approval with correspondence, ICF, drug records , staff curriculum vitae and 
authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, dat e of birth, gender)
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria)
Documentation of the reason(s) a consented subject is not enrolled
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 58 09 January 2017Participation in study  (including study  number)
Study  discussed and date of informed consent
Dates of all visits
Documentation that protocol specific procedures were performed
Results of efficacy  parameters, as required b y the protocol
Start and end date s(including dose regimen) of study  drug , including dates of dispensing and 
return
Record of all AEs and other safety  parameters (start and end date s, and including causality  
and severit y)
Concomitant medication (including start and end dates , dose if relevant ,anddose changes)
Date of stud y completion and reason for earl y discontinuation, if it occurs
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_341054] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_341055] has been enrolled. Subsequent to 
data entry , a stud
y monitor will perform source data verification within the electronic data 
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 59 09 January 2017capture ( EDC )system. Original entries as well as any  changes to data fields will be stored in the 
audit trail of the sy stem. Prior to database lock (or any  interim time points as described in the 
clinical data management plan), the investigator will use his/her lo gincredentials to confirm that 
the forms have been reviewed, and that the entries accuratel y reflect the information in the 
source documents. The eCRF capture sthe data required per the protocol schedule of events and 
procedures. System -generated or manua l queries will be issued to the investigative site staff as 
data discrepancies are identified by  [CONTACT_122045], correctness, and consistency. The site coordinator is responsible for 
responding to the queries in a timely  manner, within the sy stem, either b y confirming the data as 
correct or updating the original entry , and providing the reason for the update (eg ,data entry  
error). At the conclusion of the study , [COMPANY_009] will provide the si te with a read -only archive copy  
of the data entered b y that site. This archive must be stored in accordance with the records 
retention requirements outlined in Section 9.1.5.
9.1.7.
Study Drug Accountability and Return 
Where possible, IMP should be destro yed at the site. At the start of the study , the study  monitor 
will evaluate each stud y center’s IMP disposal procedures and provide appropriate instruction for 
disposal or return of unused IMP supplies. If the site has an appropriate standard operating 
procedure (SOP) for drug destruction as determined by  [CONTACT_10869] , the site may  destroy  
used (empt yor partially  empty ) and unused IMP supplies 
as long as performed in accordance 
with the site’s SOP. This can occur onl y after the study  monitor has performed drug 
accountability  during an on -site monitoring visit . 
A cop y of the site’s IMP Disposal SOP or written procedure (signed and dated by  [CONTACT_978] 
[INVESTIGATOR_204944]) will be obtained for [COMPANY_009] site files. If the site does not have acceptable 
procedures in place, arra ngements will be made between the siteand [COMPANY_009] Sciences 
(or[COMPANY_009] Sciences ’ representative) for return of unused study  drug supplies. 
If IMP is destro yed on site, the investigator must maintain accurate records for all IMPs
destroy ed. Upon study  completion, copi[INVESTIGATOR_279372]. Another cop y will be returned to [COMPANY_009].
9.1.8. Inspections
The investigator will make available all source documents and other records for this study to 
[COMPANY_009]’s appointed stud y monitors, to IRB/EC,or to regulatory  authorit y or health authority  
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this p rotocol.
GS-[ADDRESS_341056] submit all protocol modifications to IRB/EC in 
accordance w ith local requirements and receive documented IRB/EC approval before 
modifications may be implemented.
9.2.2. Study Report and Publications
A clinical study  report will be prepared and provided to the regulatory  agency (ies). [COMPANY_009] will 
ensure that the report mee ts the standards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases. 
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and t heir study  staff may  be asked to provide services performed under this 
protocol, eg ,attendance at i nvestigator's m eetings. If required under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to federal and state agenci es an y 
expenses paid or reimbursed for such services, including an y clinical study payments, meal, 
travel expenses or reimbursements, consulting fees, and an y other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRF. The investigator agrees to coopera te with the monitor to ensure 
that any  problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the i nvestigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify the [COMPANY_009] medical monitor immediately . The i nvestigator agrees to 
provide to representatives of a regulatory  agency  or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 61 09 January [ZIP_CODE].3.4. Study Discontinuation
Both [COMPANY_009] and the investigator reserve the right to terminate the study  at any  time. Should this 
be necessary, both parties wi ll arrange discontinuation procedures and notify  the subjects, 
appropriate regulatory  authority (ies), IRBs, and ECs .In terminating the study , [COMPANY_009] and the 
investigator will assure that adequate consideration is given to the protection of the subjects’ 
interests.
GS-[ADDRESS_341057] Sheet.  2008.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Helmick CG, Felson DT, L awrence RC, Gabriel S, Hir sch R, Kwoh CK, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the [LOCATION_002]. Part I . 
Arthritis Rheum 2008;58 (1):15-25.
Karie S, Gandjbakhch F, Janus N, L aunay -Vacher V, Rozenberg S, Mai Ba CU, et al. Kidney  
disease in RA patients: prevalence and implication on RA -related drugs 
management: the MATRIX study . Rheumatology  (Oxford) 2008;47 (3):350 -
4.
National Institute of Diabetes and Digestive and Kidney  Diseases (NIH). Estimating Glomerular 
Filtration Rate (GFR). Avail able at: https://www.niddk.nih.gov/health-
information/health -communication -programs/nkdep/lab -
evaluation/gfr/estimating/Pages/estimating.aspx . Accessed 06 October.  2016:
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 63 09 January 201711. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Management of Clinical and Laboratory Adverse Events
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 4. Common Terminology Criteria for Adverse Events (CTCAE) v 4.[ADDRESS_341058] this study as 
outlined herein and will make a reasonabl e effort to complete the study within the time 
designated. 
Twill provid e all study personnel under my supervision copi[INVESTIGATOR_279373] n provided by [CONTACT_279394] s, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed ) Signature 
[CONTACT_279395] [ADDRESS_341059] weekly until a 
return to baseline or is otherwise 
explained 1 
Study Drug may be continued witho ut dose 
interrup tion for a clinically non-significant Grade 3 
or 4 laboratory abnormality (eg, Grade 4 CK after 
strenuous exercise , or nonfasting triglyceride 
elevation , or blood in urine due to menses or that 
can be medically managed) or a clinical event 
considered unrelated to study drug. 
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 66 09 January 2017Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming postmenopausal unless the 
subject is permanentl y sterile or hasmedicall y documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are >
54years of age with 
cessation of previously  occurring menses for > [ADDRESS_341060] of an y age.
b)Definition of Male Fertility
For the purposes of this study , a male born subject is considered of fertile after the initiation of 
puberty  unless the subject is permanently  sterile by  [CONTACT_90285].
2)Contraception Requirements for Female Subjects
a)Study Drug Effects on P regnancy and Hormonal C ontraception
GS-9876 is contraindicated in pregnancy  as its teratogenicity /fetotoxicity  profile is unknown. 
GS-[ADDRESS_341061] versions of the GS -9876 IBsfor additional information.
b)Contraceptive Methods Permitted for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highly effective
contraceptive measures.  Women must agree to also not rely  on hormone -containing 
contraceptives as a form of birth control during the study , though they  may continue hormonal 
contrace ption if they  prefer to do so.  Women must have a negative serum pregnancy  test at 
Screening and a negative pregnancy  test on the Day  -[ADDRESS_341062] dose of study  drug.  
Pregnancy  tests will be performed as defined by  [CONTACT_141914] ( Table 6-1). 
GS-[ADDRESS_341063] dose of stud y drug.
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
metho
d of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal ste rilization
Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and had 
confirmation of surgical success at least 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least [ADDRESS_341064] dose of study  drug.
c)Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must agree to use condoms during treatment a nd until [ADDRESS_341065] dose of study  drug .
d)Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, 
symptothermal, post- ovulation methods), withdra wal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM).  Female condom and male condom should not be used 
together.
e)Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify the investigator if t hey become pregnant at any  time during 
the study , or if they  become pregnant within 36days of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and dis continue study  drug immediatel y.  Subjects whose partner 
has become pregnant or suspects she is pregnant during the study  or up to [ADDRESS_341066] report the information to the investigator.  Instructions for reporting 
pregna ncy, partner pregnancy , and pregnancy  outcome are outlined in Section 
[IP_ADDRESS]
GS-9876
Protocol GS -US-379-1932 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 68 09 January 2017Appendix 4. Common Terminology Criteria for Adv erse Events (CTCAE) v 4.03
CTCAE v4.03 can be accessed from the below link:
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_8.5x11.pdf
The only  modification to the CTCAE criteria is the addition of a Grade 1 upper respi[INVESTIGATOR_204946]:
CTCAE 
v4.0 Term Grade 1
Grade 2 Grade 3 Grade 4 Grade 5CTCAE v4.03 
AE Ter m 
Definition
Upper 
respi[INVESTIGATOR_204947]; 
symptomatic 
relief (eg, 
cough 
suppressant, 
decongestant)Moderate 
symptoms; 
oral 
intervention 
indicated 
(eg,antibiotic, 
antifungal, 
antiviral)IV antibiotic, 
antifungal, or 
antiviral 
intervention 
indicated; 
radiologic, 
endoscopic, or 
operative 
intervention 
indicatedLife-
threatening 
consequences; 
urgent 
intervention 
indicatedDeath A disorder 
characterized by 
[CONTACT_204985][INVESTIGATOR_4352] 
(nose, paranasal 
sinuses, pharynx, 
larynx, or 
trachea).